APHIOS CORPORATION

Basic Information

3 E GILL ST
WOBURN, MA, 01801-1720

Company Profile

n/a

Additional Details

Field Value
DUNS: 194643722
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Alzheimer's Disease Therapeutic

    Amount: $2,409,606.00

    DESCRIPTION (provided by applicant): Alzheimer's Disease (AD) is a significant neurological disorder that afflicts more than 4.5 million Americans and more than 10 million people worldwide. The l ...

    SBIR Phase II 2011 Department of Health and Human Services
  2. TAS:: 75 0896::TAS SBIR PHASE I TOPIC NCCAM 002

    Amount: $94,448.00

    This Phase I, SBIR contract is to conduct a thorough biological and phytochemical analysis of Harpagophytum procumbens. This should result in discovery of new biologically active molecules and/or a mo ...

    SBIR Phase I 2011 Department of Health and Human Services
  3. SBIR PHASE 1 TOPIC 43

    Amount: $149,440.00

    The contractor will identify methodologies for broad spectrum inactivation of pathogens in red blood cell concentrates(RBCC). RBCCs are the main components of blood used in transfusion medicine, yet c ...

    SBIR Phase I 2011 Department of Health and Human Services
  4. Alzheimer's Disease Therapeutic

    Amount: $263,690.00

    DESCRIPTION (provided by applicant): Alzheimer's Disease (AD) is a significant neurological disorder that afflicts more than 4.5 million Americans and more than 10 million people worldwide. The lack o ...

    SBIR Phase I 2010 Department of Health and Human Services
  5. CFI Inactivation of Human Plasma

    Amount: $344,267.00

    DESCRIPTION (provided by applicant): The worldwide AIDS epidemic, the periodic emergence of Ebola and SARS, and the recent outbreaks of potentially pandemic strains of influenza such as H5N1 have high ...

    SBIR Phase I 2009 Department of Health and Human Services
  6. D9-THC for Marijuana Addiction

    Amount: $109,761.00

    DESCRIPTION (provided by applicant): ?9-tetrahydrocannabinol (?9-THC) has been shown to alleviate marijuana withdrawal symptoms and thus has potential for treating cannabinoid dependence. However, the ...

    SBIR Phase I 2008 Department of Health and Human Services
  7. 402- RFP: N43-CM-87007-68 TOPIC 251: DEVELOPMENT OF ANTICANCER AGENTS REQUEST

    Amount: $149,558.00

    The aim of this project is the development of Tyrosyl DNA phosphodiesterase (Tdp1) inhibitors in order to enhance the activity of DNA topoisomerase I inhibitors.

    SBIR Phase I 2008 Department of Health and Human Services
  8. Alkylating Vitamin D Derivative

    Amount: $258,398.00

    DESCRIPTION (provided by applicant): Prostate cancer is the most prevalent cancer among men; and the second leading cause of cancer death among men in the US. There are currently no approved therapies ...

    STTR Phase I 2007 Department of Health and Human Services
  9. BIODEGRADABLE POLYMER ENCAPSULATED NANOPARTICLES FOR ORA

    Amount: $99,986.00

    N/A

    SBIR Phase I 2006 Department of Health and Human Services
  10. Development of Novel Anti-HIV Therapeutics

    Amount: $898,408.00

    DESCRIPTION (provided by applicant): Currently, there are 42 million AIDS cases worldwide, with a majority present in the third world; 3.1 million deaths can be attributed to HIV and AIDS in 2002 alo ...

    SBIR Phase I 2004 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government